259 related articles for article (PubMed ID: 33921589)
1. Characterization of Subtype Selective Cannabinoid CB
Tang Y; Wolk B; Nolan R; Scott CE; Kendall DA
Pharmaceuticals (Basel); 2021 Apr; 14(4):. PubMed ID: 33921589
[TBL] [Abstract][Full Text] [Related]
2. Anti-inflammatory and antinociceptive effects of the selective cannabinoid CB
Tang Y; Wolk B; Britch SC; Craft RM; Kendall DA
J Pharmacol Sci; 2021 Apr; 145(4):319-326. PubMed ID: 33712283
[TBL] [Abstract][Full Text] [Related]
3. Effects of a CB
Tang Y; Wolk B; Kendall DA
J Cell Signal; 2021; 2(2):85-93. PubMed ID: 34263256
[TBL] [Abstract][Full Text] [Related]
4. Identification and biochemical analyses of selective CB
Scott CE; Tang Y; Alt A; Burford NT; Gerritz SW; Ogawa LM; Zhang L; Kendall DA
Eur J Pharmacol; 2019 Jul; 854():1-8. PubMed ID: 30951717
[TBL] [Abstract][Full Text] [Related]
5. Structure-Effect Relationships of Novel Semi-Synthetic Cannabinoid Derivatives.
Götz MR; Collado JA; Fernández-Ruiz J; Fiebich BL; García-Toscano L; Gómez-Cañas M; Koch O; Leha A; Muñoz E; Navarrete C; Pazos MR; Holzgrabe U
Front Pharmacol; 2019; 10():1284. PubMed ID: 31824305
[No Abstract] [Full Text] [Related]
6. Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy.
Valenzano KJ; Tafesse L; Lee G; Harrison JE; Boulet JM; Gottshall SL; Mark L; Pearson MS; Miller W; Shan S; Rabadi L; Rotshteyn Y; Chaffer SM; Turchin PI; Elsemore DA; Toth M; Koetzner L; Whiteside GT
Neuropharmacology; 2005 Apr; 48(5):658-72. PubMed ID: 15814101
[TBL] [Abstract][Full Text] [Related]
7. Indole compounds with
Li J; Ji J; Xu R; Li Z
Medchemcomm; 2019 Nov; 10(11):1935-1947. PubMed ID: 32952995
[TBL] [Abstract][Full Text] [Related]
8. A role for cannabinoid receptors, but not endogenous opioids, in the antinociceptive activity of the CB2-selective agonist, GW405833.
Whiteside GT; Gottshall SL; Boulet JM; Chaffer SM; Harrison JE; Pearson MS; Turchin PI; Mark L; Garrison AE; Valenzano KJ
Eur J Pharmacol; 2005 Dec; 528(1-3):65-72. PubMed ID: 16316650
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, in vitro and in vivo evaluation of 1,3,5-triazines as cannabinoid CB2 receptor agonists.
Yrjölä S; Sarparanta M; Airaksinen AJ; Hytti M; Kauppinen A; Pasonen-Seppänen S; Adinolfi B; Nieri P; Manera C; Keinänen O; Poso A; Nevalainen TJ; Parkkari T
Eur J Pharm Sci; 2015 Jan; 67():85-96. PubMed ID: 25447744
[TBL] [Abstract][Full Text] [Related]
10. Discovery of novel Tetrahydrobenzo[b]thiophene and pyrrole based scaffolds as potent and selective CB2 receptor ligands: The structural elements controlling binding affinity, selectivity and functionality.
Osman NA; Ligresti A; Klein CD; Allarà M; Rabbito A; Di Marzo V; Abouzid KA; Abadi AH
Eur J Med Chem; 2016 Oct; 122():619-634. PubMed ID: 27448919
[TBL] [Abstract][Full Text] [Related]
11. The curative effect of cannabinoid 2 receptor agonist on functional failure and disruptive inflammation caused by intestinal ischemia and reperfusion.
Bayram S; Parlar A; Arslan SO
Fundam Clin Pharmacol; 2020 Feb; 34(1):80-90. PubMed ID: 31373049
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of inflammatory hyperalgesia by activation of peripheral CB2 cannabinoid receptors.
Quartilho A; Mata HP; Ibrahim MM; Vanderah TW; Porreca F; Makriyannis A; Malan TP
Anesthesiology; 2003 Oct; 99(4):955-60. PubMed ID: 14508331
[TBL] [Abstract][Full Text] [Related]
13. Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor.
Klegeris A; Bissonnette CJ; McGeer PL
Br J Pharmacol; 2003 Jun; 139(4):775-86. PubMed ID: 12813001
[TBL] [Abstract][Full Text] [Related]
14. The cannabinoid 2 receptor agonist β-caryophyllene modulates the inflammatory reaction induced by Mycobacterium bovis BCG by inhibiting neutrophil migration.
Andrade-Silva M; Correa LB; Candéa AL; Cavalher-Machado SC; Barbosa HS; Rosas EC; Henriques MG
Inflamm Res; 2016 Nov; 65(11):869-879. PubMed ID: 27379721
[TBL] [Abstract][Full Text] [Related]
15. Biological characterization of PM226, a chromenoisoxazole, as a selective CB2 receptor agonist with neuroprotective profile.
Gómez-Cañas M; Morales P; García-Toscano L; Navarrete C; Muñoz E; Jagerovic N; Fernández-Ruiz J; García-Arencibia M; Pazos MR
Pharmacol Res; 2016 Aug; 110():205-215. PubMed ID: 27013280
[TBL] [Abstract][Full Text] [Related]
16. Effects of pro-inflammatory cytokines on cannabinoid CB1 and CB2 receptors in immune cells.
Jean-Gilles L; Braitch M; Latif ML; Aram J; Fahey AJ; Edwards LJ; Robins RA; Tanasescu R; Tighe PJ; Gran B; Showe LC; Alexander SP; Chapman V; Kendall DA; Constantinescu CS
Acta Physiol (Oxf); 2015 May; 214(1):63-74. PubMed ID: 25704169
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of selective cannabinoid CB(1) and CB(2) receptor agonists in a mouse model of lipopolysaccharide-induced interstitial cystitis.
Tambaro S; Casu MA; Mastinu A; Lazzari P
Eur J Pharmacol; 2014 Apr; 729():67-74. PubMed ID: 24561047
[TBL] [Abstract][Full Text] [Related]
18. Synthetic cannabinoid WIN55,212-2 inhibits generation of inflammatory mediators by IL-1beta-stimulated human astrocytes.
Sheng WS; Hu S; Min X; Cabral GA; Lokensgard JR; Peterson PK
Glia; 2005 Jan; 49(2):211-9. PubMed ID: 15390091
[TBL] [Abstract][Full Text] [Related]
19. Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630.
Ross RA; Brockie HC; Stevenson LA; Murphy VL; Templeton F; Makriyannis A; Pertwee RG
Br J Pharmacol; 1999 Feb; 126(3):665-72. PubMed ID: 10188977
[TBL] [Abstract][Full Text] [Related]
20. Structure-activity relationships of thiazole and benzothiazole derivatives as selective cannabinoid CB2 agonists with in vivo anti-inflammatory properties.
Ghonim AE; Ligresti A; Rabbito A; Mahmoud AM; Di Marzo V; Osman NA; Abadi AH
Eur J Med Chem; 2019 Oct; 180():154-170. PubMed ID: 31302448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
